ArticleHeliyon2024
Dual vision Transformer-DSUNET with feature fusion for brain tumor segmentation.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- BRAIN-META: A reproducible CNN-vision transformer meta-ensemble pipeline for explainable brain tumor classification.MethodsX · 2026Article
- FMCL: a transformer-based feature-map classifier learning approach for enhanced brain tumor detection in MRI.Scientific reports · 2026Article
- Interpretability and performance of a 3D C-vit model for accurate grading of pediatric brain tumors.Frontiers in oncology · 2026Article
- ResSAXU-Net for multimodal brain tumor segmentation from brain MRI.Scientific reports · 2025Article
- Dual-Stream Contrastive Latent Learning Generative Adversarial Network for Brain Image Synthesis and Tumor Classification.Journal of imaging · 2025Article
- A hybrid MMBERT framework for classifying periodontal bone loss: Integrating visual and textual information.Journal of oral biology and craniofacial researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain tumors are one of the leading causes of cancer death; screening early is the best strategy to diagnose and treat brain tumors. Magnetic Resonance Imaging (MRI) is extensively utilized for brain tumor diagnosis; nevertheless, achieving improved accuracy and performance, a critical challenge in most of the previously reported automated medical diagnostics, is a complex problem. The study introduces the Dual Vision Transformer-DSUNET model, which incorporates feature fusion techniques to provide precise and efficient differentiation between brain tumors and other brain regions by leveraging multi-modal MRI data. The impetus for this study arises from the necessity of automating the segmentation process of brain tumors in medical imaging, a critical component in the realms of diagnosis and therapy strategy. The BRATS 2020 dataset is employed to tackle this issue, an extensively utilized dataset for segmenting brain tumors. This dataset encompasses multi-modal MRI images, including T1-weighted, T2-weighted, T1Gd (contrast-enhanced), and FLAIR modalities. The proposed model incorporates the dual vision idea to comprehensively capture the heterogeneous properties of brain tumors across several imaging modalities. Moreover, feature fusion techniques are implemented to augment the amalgamation of data originating from several modalities, enhancing the accuracy and dependability of tumor segmentation. The Dual Vision Transformer-DSUNET model's performance is evaluated using the Dice Coefficient as a prevalent metric for quantifying segmentation accuracy. The results obtained from the experiment exhibit remarkable performance, with Dice Coefficient values of 91.47 % for enhanced tumors, 92.38 % for core tumors, and 90.88 % for edema. The cumulative Dice score for the entirety of the classes is 91.29 %. In addition, the model has a high level of accuracy, roughly 99.93 %, which underscores its durability and efficacy in segmenting brain tumors. Experimental findings demonstrate the integrity of the suggested architecture, which has quickly improved the detection accuracy of many brain diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.